There’s Still Time to Buy Coherus Biosciences Inc (NASDAQ:CHRS) Stock

In yesterday’s Wall Street session, Coherus Biosciences Inc (NASDAQ:CHRS) shares traded at $2.30, down -2.95% from the previous session. CHRS stock price is now -15.28% away from the 50-day moving average and -51.44% away from the 200-day moving average. The market capitalization of the company currently stands at $256.13M. With the price target of $11, […]

Reasons why Coherus Biosciences Inc’s (NASDAQ:CHRS) fundamentals are futile

In yesterday’s Wall Street session, Coherus Biosciences Inc (NASDAQ:CHRS) shares traded at $2.13, up 24.56% from the previous session. 9 analysts cover Coherus Biosciences Inc (NASDAQ:CHRS), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a […]

Reasons why Coherus Biosciences Inc’s (NASDAQ:CHRS) fundamentals are futile

In yesterday’s Wall Street session, Coherus Biosciences Inc (NASDAQ:CHRS) shares traded at $2.47, down -30.23% from the previous session. 9 analysts cover Coherus Biosciences Inc (NASDAQ:CHRS), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a […]

How should investors evaluate Coherus Biosciences Inc (NASDAQ:CHRS)?

Stocks of Coherus Biosciences Inc (NASDAQ:CHRS) traded higher last session on Wall Street, up 14.02% to $3.01. According to the data, Coherus Biosciences Inc (NASDAQ:CHRS) has 9 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. CHRS stock price is now -28.01% away from the 50-day moving average and -47.18% away from the […]

Can Coherus BioSciences Inc. (CHRS) stock recover despite sales dropping?

In yesterday’s Wall Street session, Coherus BioSciences Inc. (NASDAQ:CHRS) shares traded at $4.14, down -8.20% from the previous session. 9 analysts cover Coherus BioSciences Inc. (NASDAQ:CHRS), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $20.00 and a […]